Abstract:Background and objective: Methylmalonic acidemia (MMA) and propionic acidemia (PA) are rare inborn errors of metabolism with shared signs and symptoms that are associated with significant morbidity and mortality. No disease-specific clinical outcomes assessment instruments for MMA and/or PA currently exist to capture the patient perspective in clinical trials. Because patients with these conditions are generally young and have cognitive impairments, an observer-reported outcome (ObsRO) instrument is crucial. We report results from qualitative research supporting development of the Methylmalonic Acidemia and Propionic Acidemia Questionnaire (MMAPAQ), a signs and symptoms ObsRO measure for caregivers of patients with MMA and/or PA. Methods: Concept elicitation (CE) interviews were conducted with 35 participants across 2 studies who were aged ≥18 years and caregivers of patients with a confirmed diagnosis of MMA or PA, and an additional 5 patients aged ≥6 years with MMA or PA in Study 1, to identify core signs/symptoms for inclusion in the MMAPAQ. All interviews were conducted in English. Study 2 included cognitive interviews (CI) with caregivers and clinical experts to further assess content validity. CE and a conceptual framework review were also conducted with clinical experts to further support findings. Results: A consistent set of signs/symptoms of MMA and PA were reported by eligible caregivers interviewed in study 1 (n = 21) and study 2 (n = 14), representing 11 patients with MMA and 20 with PA. Based on concepts reported in study 1, a draft instrument was constructed and compared with the Pediatric Quality of Life Inventory™ (PedsQL™) and Family Impact module, demonstrating face validity for measuring key signs/symptoms important to patients and caregivers. The PedsQL™ and Family Impact modules were preferred to assess patient and caregiver impacts. Two waves of CE and CIs were conducted in study 2, with wave 1 resulting in removal of 7 items and other revisions to improve clarity, and wave 2 resulting in modification of examples used for 2 items. The final instrument consisted of the following 7 items assessed over the past 7 days using a Likert-type response scale ranging from "never" to "very often": uncontrollable or involuntary movements, dehydration, rapid breathing at rest, appearing lethargic, appearing disinterested in eating, refusing to eat, and vomiting. Conclusions: This study establishes the content validity of the MMAPAQ as the first ObsRO questionnaire for measuring core signs and symptoms of MMA and PA in clinical trials and community research. Scoring and psychometric measurement properties of the MMAPAQ will be established in future studies. The PedsQL™ was found to have face validity in measuring concepts that affect the MMA and PA patient populations and should also be considered for use in clinical trials in MMA and PA.

Behavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders

Impact of age at onset and newborn screening on outcome in organic acidurias

Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set

Severity-adjusted evaluation of initial dialysis on short-term health outcomes in urea cycle disorders

Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium

Unmet Needs of Parents of Children with Urea Cycle Disorders

Clinical findings of patients with hyperammonemia affected by urea cycle disorders with hepatic encephalopathy

Organic acid disorders

Fifteen years of urea cycle disorders brain research: Looking back, looking forward

Clinical Onset and Prognosis of Asian Children with Organic Acidemias, As Detected by Analysis of Urinary Organic Acids Using GC/MS, Instead of Mass Screening

Liver and/or kidney transplantation in amino and organic acid‐related inborn errors of metabolism: An overview on European data

Clinical and Laboratory Study on Late-Onset Urea Cycle Defects

Assessment of quality of life in families affected by maple syrup urine disease: a cross sectional study

Intellectual Disabilities and Neurocognitive Impairment in Adult Patients with Inherited Metabolic Diseases: A UK Single Centre Experience

[Clinical and Laboratory Screening Studies on Urea Cycle Defects].

Development of a signs and symptoms outcome measure for caregivers of patients with methylmalonic acidemia and propionic acidemia (MMAPAQ)

Two inborn errors of metabolism in a newborn: glutaric aciduria type I combined with isobutyrylglycinuria

The Application of Next-Generation Sequencing (NGS) in Neonatal-Onset Urea Cycle Disorders (UCDs): Clinical Course, Metabolomic Profiling, and Genetic Findings in Nine Chinese Hyperammonemia Patients

Variable disease manifestations and metabolic management within a single family affected by ornithine transcarbamylase deficiency

Choosing between medical management and liver transplant in urea cycle disorders: A conceptual framework for parental treatment decision‐making in rare disease

Long‐term outcome of urea cycle disorders: Report from a nationwide study in Japan